MURA

Mural Oncology

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 1

Sell signal 1

consensus rating "Strong Buy"

EPS Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About MURA

Mural Oncology Plc

A clinical-stage company focused on tumor immunotherapy

Industry

Pharmaceutical

Established Date

Invalid Date

Listing Date

11/16/2023

Exchange

NASDAQ Stock Exchange

Full-time Employees

116

Fiscal Year Ends

12-31

Website

www.muraloncology.com

Security Type

Common stock

Office address

10 Earlsfort Terrace, Dublin 2, D02 T380, Ireland

Business

Introduction

Mural Oncology plc is an Irish registered public limited company established in May 2017 as a private limited company. On August 21, 2023, the company was re-registered as a public limited company and changed its name to Mural Oncology plc. The company is a clinical-stage oncology company focused on discovering and developing immunotherapies that may meaningfully improve the lives of cancer patients. By leveraging the Company's core competencies in immune cell regulation and protein engineering, the Company has developed a range of novel investigational cytokine therapies designed to address areas of unmet need in a variety of cancer patients. The Company's lead product candidate, nemvaleukin alfa (" nemvaleukin "), is an investigational, engineered interleukin-2 (" IL-2 ") cytokine designed to capture and amplify the therapeutic benefits of high-dose recombinant human IL-2 (" rhIL-2 ") while mitigating its hallmark toxicity.

Company Financials

EPS

MURA has released its 2024 Q4 earnings. EPS was reported at -2.01, versus the expected -1.96, missing expectations. The chart below visualizes how MURA has performed over recent quarters, highlighting trends in earnings surprises.